In the latest issue of ASCCA, we delve into the complexities of Advanced Therapy Medicinal Products (ATMP) production and its implications on both costs and environmental impact. ATMP production is characterized by high direct costs, but it also incurs substantial indirect expenses related to qualifications, validations, and essential infrastructure.
Our analysis compares the greenhouse gas (GHG) emissions in CO2 equivalent of traditional cleanrooms (open systems) against closed systems equipped with isolators. We assess the energy requirements, ecological footprints, and associated costs over a 21-day production cycle.
To explore our findings and understand how these insights can lead to more sustainable practices in ATMP production, we invite you to read the full article here.
CORPORATE
ITALY
FRANCE
GERMANY
UK
CHINA